Company Overview and News


Add MTZPY
to your dashboard

Headline News

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2017 Update

2017-11-21 seekingalpha
Halvorsen's 13F portfolio value increased from $14.85B to $15.44B. The number of positions increased from 53 to 59. (1331-5)

Akebia Therapeutics Is A Buy With The Recent Stock Price Pullback

2017-11-10 seekingalpha
This was written for our subscribers last week, and since then the stock is down 15% on EPS loss. (19-0)

VIVUS Reports Third Quarter 2017 Financial Results

2017-11-07 marketwired
CAMPBELL, CA--(Marketwired - November 07, 2017) - VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial results for the quarter ended September 30, 2017 and provided a business update. (11-0)

Qumu's (QUMU) CEO Vernon Hanzlik on Q3 2017 Results - Earnings Call Transcript

2017-11-01 seekingalpha
Good day, ladies and gentlemen, and welcome to the Qumu Third Quarter 2017 Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] (6-0)

Corbus Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of Directors

2017-10-17 marketwired
NORWOOD, MA--(Marketwired - October 17, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has appointed Mr. Paris Panayiotopoulos to its Board of Directors. (152-0)

Mitsubishi Tanabe Pharma (MTZPY) Investor Presentation - Slideshow

2017-09-27 seekingalpha
The following slide deck was published by Mitsubishi Tanabe Pharma Corp. ADR in conjunction with this event. (2-0)

Akebia Hits a New High as Kidney Disease Drug Meets Mid-Stage Trial Goals

2017-09-26 biospace
- Akebia Provides Mitsubishi Tanabe with Option to Access Global Phase 3 Vadadustat Data for Payments of up to $25 Million - (19-0)

Zoetis: Demanding Attention

2017-09-15 seekingalpha
With growing awareness about animal health, companies are growing more conscious of treating animals in a socially acceptable manner. If you look at prominent makeup brands, a lot of these multi-million dollar companies make explicit claims about livestock health and responsible handling. Similarly, with research and surveys discovering more complex diseases, the health sector is working overtime to find cures for healthier livestock.

Swoop In To Pick Up Regeneron This Month

2017-09-14 seekingalpha
Eylea continues to witness solid demand in approved indications. Besides, the company is striving to further expand the drug’s label. (1-0)

First FDA-Approved Treatment For ALS In 22 Years Now Available In U.S.

2017-08-08 devicespace
JERSEY CITY, N.J., Aug. 8, 2017 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc., today announced RADICAVA (edaravone), an intravenous therapy indicated for all adult patients diagnosed with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is now available for treatment in the United States. RADICAVA, the first FDA-approved ALS treatment option in more than 20 years, has been demonstrated to slow the decline in the loss of physical function in ALS patients by 33 percent in its clinical trial.

Daiichi Sankyo Company's (DSKYF) Management on Q1 2018 Results - Earnings Call Transcript

2017-08-05 seekingalpha
Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q1 2018 Earnings Conference Call July 31, 2017 12:00 PM ET

Neurocrine Biosciences Reports Second Quarter 2017 Results

2017-08-03 prnewswire
- INGREZZA® Net Product Sales of $6.3 Million in Initial Two Months of Commercialization as the First and Only U.S. Food and Drug Administration Approved Product for the Treatment of Tardive Dyskinesia - Partner AbbVie Expected to Submit Elagolix NDA for Endometriosis During the Third Quarter of 2017 and Pay $30 Million Milestone in Fourth Quarter of 2017 - Partner Mitsubishi Tanabe Expected to Initiate Pivotal Trial of INGREZZA in Asia for the Treatment of Tardive Dyskinesia and Pay $15 Million in Milestones during Third Quarter of 2017 - Completed Offering of $517.

VIVUS Reports Second Quarter 2017 Financial Results

2017-08-03 marketwired
CAMPBELL, CA--(Marketwired - August 03, 2017) - VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial results for the quarter ended June 30, 2017 and provided a business update.

Regeneron Reports Second Quarter 2017 Financial and Operating Results

2017-08-03 prnewswire
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2017 and provided a business update.

Featured Company News - NeuroDerm to be acquired by Mitsubishi Tanabe Pharma Corp.

2017-07-26 accesswire
LONDON, UK / ACCESSWIRE / July 26, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for NeuroDerm Ltd (NASDAQ: NDRM), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=NDRM. The Israel-based pharmaceutical Company, which is known for developing drug-device combinations for central nervous system (CNS) disorders, announced on July 24, 2017, that it has signed a definitive agreement to be acquired by the Japanese pharmaceutical company, Mitsubishi Tanabe Pharma Corporation ("MTPC").

CUSIP: 606813202